Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine

Review

Raymond J. Foley¹  Shireen Mirza¹ 

[1]Pulmonary and Critical Care Medicine Division, University of Connecticut School of Medicine, Farmington, CT.

关键词: pulmonary arterial hypertension;    treprostinil;    epoprostenol;    prostanoids;    six minute walk distance;    New York Heart Association functional class;    hemodynamics;   

DOI  :  10.4137/CCRPM.S8678

来源: Sage Journals

【 摘 要 】

Pulmonary arterial hypertension (PAH) is a disease that leads to characteristic vascular wall remodeling and hemodynamic alterations. Consequently, this pulmonary vascular disease contributes to substantial morbidity and mortality in afflicted patients. PAH may be idiopathic in nature or associated with connective tissue disease, chronic liver disease, human immunodeficiency virus, congenital heart disease, and a growing list of other conditions. There are currently nine Food and Drug Administration-approved therapies for specific PAH treatment. Therapeutic targets include prostacyclin replacement, endothelin-1 antagonism, and phosphodiesterase-5 inhibition. This article focuses on the prostanoid treprostinil and explores its role in the management of patients with PAH.

【 授权许可】

CC BY-NC   
© 2012 SAGE Publications.